NeuroFlow is teaming up with a genetic testing biz to advance its mental health platform

Mental health platform NeuroFlow has been making moves this year.

When we checked in with the 2019 realLIST company last month, the team had grown its staff to 26, was on pace to do more than $2 million in annual revenue by the end of the year, and had partnered with Jefferson Health to create a mental healthcare platform that facilitates health care management for patients in between traditional office visits.

Now, NeuroFlow has joined forces with another local healthtech venture — King of Prussia-based Genomind, which uses genetic testing to inform and aide doctors in mental health treatment.

The companies announced the partnership Monday, saying they’re bringing their technology and clinical services together to share information, but will remain independent entities.

“NeuroFlow’s IntegrateHealth platform now sources Genomind’s data, and vice versa,” a spokesperson said.

Genomind’s flagship product is the Professional PGx Express, a genetic test via cheek swab that analyzes a set of 24 genes for conditions like depression, anxiety, autism, schizophrenia, chronic pain, bipolar disorder, obsessive-compulsive disorder, attention deficit hyperactivity disorder, post-traumatic stress disorder and substance abuse.

Physicians using NeuroFlow’s IntegrateHealth application will be able to administer Professional PGx Express to their patients and communicate results within the platform.

The service provides test results to physicians within three days, and NeuroFlow’s software enables remote patient monitoring, risk stratification and behavioral health integration across multiple medical care settings, including psychology, primary care and pain management specialties.

“From the beginning, we’ve been excited to align our resources and technologies with Genomind in order to optimize the way behavioral health is assessed, measured, and treated,” NeuroFlow CEO and cofounder Chris Molaro said in a statement.

Genomind CEO Shawn Patrick O’Brien said he believes the collaboration to be one of the only of its kind.

“Our collaboration with NeuroFlow is a strategic fit of complementary missions — using data-driven innovations to get patients the care they need faster,” he said. “Our work together improves access to care, informs treatment, reduces costs, and tracks outcomes across the entire continuum of the treatment cycle.”

The partnership between companies was official Monday, and clinicians interested in using the services can reach out to either company for more information.